BioVie To Present Data Showing How NE3107 Potentially Restores Homeostasis Via Specific Genes Associated With Dementia, Metabolism, And Inflammation
BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an oral presentation and poster presentation will be shared at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit to be held in Boston, Massachusetts April 23-25.
Additionally, the United States Adopted Names (USAN) Council, and the World Health Organization (WHO) International Nonproprietary Names (INN) expert committee has approved "bezisterim" as the non-proprietary (generic) name for NE3107, an orally active partial NF-κB inhibitor product candidate being studied in Parkinson's Disease and Alzheimer's Disease.
The oral and poster presentations 12th Annual Alzheimer's & Parkinson's Drug Development Summit will provide additional details on how bezisterim appears to have an impact on DNA methylation on 5 different "clocks" measuring biological age and that the extent of DNA methylation is correlated to a series of clinical measures.
The oral presentation titled "Clinical Outcomes and Biomarker Findings from a Randomized, Placebo-Controlled Trial of NE3107 in Subjects with Mild to Moderate Probably Alzheimer's Disease" will be presented by Christopher L. Reading, BioVie's Senior Vice President, Alzheimer's Disease Program, on Wednesday, April 24 at 2:30 p.m. EDT. The poster with the same title will be presented at 6:45 p.m. on the same day.
Details of the presented data and conclusions will be announced once the presentations are made public at the conference.